HIV 1/2 Ab Test Strip
ATR018-1
Antonmed HIV 1/2 Ab Test Strip is a rapid lateral flow immunoassay designed for the qualitative detection of antibodies to Human Immunodeficiency Virus type 1 (HIV-1) and type 2 (HIV-2) in the specified human specimen.
Delivery:
FOB, FCA, DDP
minimum order:
200 pieces
Supply Ability:
2000000pieces / Month
Country of Origin:
China
Stock Time:
7Day
Quantity:
Introduction
Antonmed HIV 1/2 Ab Test Strip is a rapid lateral flow immunoassay designed for the qualitative detection of antibodies to Human Immunodeficiency Virus type 1 (HIV-1) and type 2 (HIV-2) in the specified human specimen.
The strip format provides a compact testing solution without the need for dedicated laboratory instrumentation. Depending on the validated product configuration and intended use, the test can be supplied for professional diagnostic applications and other authorized testing settings.
Antonmed also provides OEM and private-label solutions for distributors, diagnostic companies and healthcare brands looking to develop or expand their rapid testing portfolios.
The strip format provides a compact testing solution without the need for dedicated laboratory instrumentation. Depending on the validated product configuration and intended use, the test can be supplied for professional diagnostic applications and other authorized testing settings.
Antonmed also provides OEM and private-label solutions for distributors, diagnostic companies and healthcare brands looking to develop or expand their rapid testing portfolios.
Key Features
HIV-1 and HIV-2 Antibody Detection – Designed for qualitative detection of antibodies associated with HIV-1 and HIV-2.
Rapid Lateral Flow Format – Uses chromatographic immunoassay technology for rapid visual testing.
Simple Testing Procedure – Designed for straightforward specimen application and result interpretation.
Visual Result – Control and test lines allow qualitative interpretation according to the Instructions for Use.
No Dedicated Analyzer Required – The strip format is designed for visual reading.
Compact Test Format – Suitable for individual packaging and multi-test configurations.
Flexible Packaging – Packaging options can be adapted for different B2B requirements.
OEM & Private Label Support – Branding, packaging and labeling solutions are available for qualified customers.
HIV-1 and HIV-2 Antibody Detection – Designed for qualitative detection of antibodies associated with HIV-1 and HIV-2.
Rapid Lateral Flow Format – Uses chromatographic immunoassay technology for rapid visual testing.
Simple Testing Procedure – Designed for straightforward specimen application and result interpretation.
Visual Result – Control and test lines allow qualitative interpretation according to the Instructions for Use.
No Dedicated Analyzer Required – The strip format is designed for visual reading.
Compact Test Format – Suitable for individual packaging and multi-test configurations.
Flexible Packaging – Packaging options can be adapted for different B2B requirements.
OEM & Private Label Support – Branding, packaging and labeling solutions are available for qualified customers.
Intended Use
Antonmed HIV 1/2 Ab Test Strip is intended for the qualitative detection of antibodies to HIV-1 and HIV-2 in the specimen specified in the product's Instructions for Use.
Antonmed HIV 1/2 Ab Test Strip is intended for the qualitative detection of antibodies to HIV-1 and HIV-2 in the specimen specified in the product's Instructions for Use.
The test is intended to be used as an aid in HIV testing according to the applicable product labeling, regulatory requirements and testing algorithm.
The product should only be used for the intended purpose and in the intended setting described in its approved documentation.
Important: A reactive result is not, by itself, a definitive diagnosis of HIV infection. Reactive specimens should be tested using an appropriate supplemental or confirmatory method in accordance with applicable clinical and regulatory guidelines.
This distinction is particularly important for HIV rapid testing. WHO's HIV testing guidance treats rapid tests as components of validated testing strategies rather than standalone confirmation of infection.
